Nurix Therapeutics, Inc. (NASDAQ:NRIX) Receives $29.40 Consensus PT from Brokerages

Nurix Therapeutics, Inc. (NASDAQ:NRIX) has been assigned an average rating of “Moderate Buy” from the fifteen ratings firms that are presently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a hold rating and fourteen have issued a buy rating on the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $29.40.

Several research firms recently commented on NRIX. Jefferies Financial Group began coverage on shares of Nurix Therapeutics in a research note on Friday, October 11th. They set a “buy” rating and a $41.00 price objective on the stock. Oppenheimer lifted their target price on shares of Nurix Therapeutics from $27.00 to $30.00 and gave the company an “outperform” rating in a report on Wednesday, September 4th. HC Wainwright lifted their target price on shares of Nurix Therapeutics from $26.00 to $30.00 and gave the company a “buy” rating in a report on Monday, October 21st. Stephens reiterated an “overweight” rating and set a $31.00 target price on shares of Nurix Therapeutics in a report on Monday, October 14th. Finally, Robert W. Baird began coverage on shares of Nurix Therapeutics in a report on Friday, September 6th. They set an “outperform” rating and a $26.00 target price for the company.

Nurix Therapeutics Trading Down 4.5 %

Shares of Nurix Therapeutics stock opened at $24.07 on Monday. The company’s fifty day simple moving average is $24.18 and its two-hundred day simple moving average is $20.17. The company has a market cap of $1.71 billion, a P/E ratio of -8.27 and a beta of 2.22. Nurix Therapeutics has a 12-month low of $4.96 and a 12-month high of $27.60.

Nurix Therapeutics (NASDAQ:NRIX) last announced its earnings results on Friday, October 11th. The company reported ($0.67) EPS for the quarter, meeting analysts’ consensus estimates of ($0.67). The firm had revenue of $12.59 million for the quarter, compared to analysts’ expectations of $13.85 million. Nurix Therapeutics had a negative net margin of 313.65% and a negative return on equity of 63.39%. Analysts predict that Nurix Therapeutics will post -2.84 EPS for the current fiscal year.

Insiders Place Their Bets

In other Nurix Therapeutics news, insider Gwenn Hansen sold 3,437 shares of Nurix Therapeutics stock in a transaction that occurred on Wednesday, October 30th. The shares were sold at an average price of $24.30, for a total value of $83,519.10. Following the completion of the sale, the insider now owns 50,670 shares of the company’s stock, valued at approximately $1,231,281. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, insider Gwenn Hansen sold 3,437 shares of Nurix Therapeutics stock in a transaction on Wednesday, October 30th. The shares were sold at an average price of $24.30, for a total transaction of $83,519.10. Following the transaction, the insider now owns 50,670 shares in the company, valued at $1,231,281. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Houte Hans Van sold 20,000 shares of Nurix Therapeutics stock in a transaction on Monday, August 26th. The shares were sold at an average price of $25.22, for a total transaction of $504,400.00. Following the transaction, the chief financial officer now owns 31,002 shares in the company, valued at approximately $781,870.44. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 53,775 shares of company stock valued at $1,328,312. Company insiders own 9.80% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Amalgamated Bank lifted its stake in Nurix Therapeutics by 30.6% in the 3rd quarter. Amalgamated Bank now owns 2,182 shares of the company’s stock worth $49,000 after purchasing an additional 511 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in Nurix Therapeutics by 31.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,330 shares of the company’s stock worth $54,000 after purchasing an additional 559 shares in the last quarter. ProShare Advisors LLC lifted its stake in Nurix Therapeutics by 9.1% in the 1st quarter. ProShare Advisors LLC now owns 11,978 shares of the company’s stock worth $176,000 after purchasing an additional 998 shares in the last quarter. ClariVest Asset Management LLC lifted its stake in Nurix Therapeutics by 2.9% in the 2nd quarter. ClariVest Asset Management LLC now owns 63,149 shares of the company’s stock worth $1,318,000 after purchasing an additional 1,766 shares in the last quarter. Finally, Public Employees Retirement System of Ohio lifted its stake in Nurix Therapeutics by 3.7% in the 1st quarter. Public Employees Retirement System of Ohio now owns 50,838 shares of the company’s stock worth $747,000 after purchasing an additional 1,820 shares in the last quarter.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.